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Abstract
Background: Consistent with fulminant endothelial cell activation, elevated plasma 
von Willebrand factor (VWF) antigen levels have been reported in patients with 
COVID- 19. The multimeric size and function of VWF are normally regulated through 
A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 
13 (ADAMTS- 13)- - mediated proteolysis.
Objectives: This study investigated the hypothesis that ADAMTS- 13 regulation of 
VWF multimer distribution may be impaired in severe acute respiratory syndrome- 
coronavirus- 2 (SARS- CoV- 2) infection contributing to the observed microvascular 
thrombosis.
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1  |  INTRODUC TION
The severe acute respiratory syndrome- coronavirus- 2 (SARS- CoV- 2) 
pandemic has already been responsible for more than 2 million 
deaths caused by severe bilateral pneumonia, venous thrombo-
embolism, and microvascular thrombosis that results in significant 
hypoxia. Although the pathogenic mechanisms contributing to this 
pneumonia remain poorly understood, autopsy studies in COVID- 19 
patients have reported disseminated thrombosis, microangiopa-
thy, and angiogenesis within the pulmonary microvasculature.1,2 
These post- mortem studies also highlighted significant endothelial 
cell (EC) damage within the lungs, including loss of EC tight junc-
tions, separation of EC from basement membranes, and EC apopto-
sis. Interestingly, EC expresses the angiotensin- converting enzyme 
2 receptor and electron microscopy analysis has demonstrated 
the presence of SARS- CoV- 2 within EC.3 A number of other path-
ways have also been implicated in EC injury in patients with severe 
COVID- 19 (e.g., hypoxia, complement pathway activation, and pro- 
inflammatory cytokine production).4
Clinical studies have demonstrated that COVID- 19 is associated 
with a characteristic coagulopathy. Given the normal role of ECs in 
regulating thrombin generation, von Willebrand factor (VWF) re-
lease and platelet adhesion and activation, it seems likely that EC 
damage is critical in triggering this coagulopathy and propensity for 
thrombosis. Consistent with that concept, we and others have ob-
served markedly elevated plasma VWF antigen (VWF:Ag) and VWF 
propeptide (VWF:pp) levels in patients with severe COVID- 19.5,6 
Indeed, patients with severe SARS- CoV- 2 had VWF:pp levels higher 
than those seen in other fulminant vascular disorders such as throm-
botic thrombocytopenic purpura (TTP). The striking increases in 
plasma VWF levels are sustained over weeks and recent studies have 
reported that higher plasma VWF:Ag and VWF:pp levels correlate 
with worse clinical outcomes in patients with severe COVID- 19.5 
Critically, however, it remains unclear whether the increased VWF 
levels play any direct role in modulating microvascular occlusion 
within the lungs, or whether they merely represent a biomarker of 
acute EC activation and damage.
Patients and Methods: Patients with COVID- 19 (n = 23) were recruited from the 
Beaumont Hospital Intensive Care Unit (ICU) in Dublin. Plasma VWF antigen, mul-
timer distribution, ADAMTS- 13 activity, and known inhibitors thereof were assessed.
Results: We observed markedly increased VWF collagen- binding activity in pa-
tients with severe COVID- 19 compared to controls (median 509.1 versus 94.3 IU/dl). 
Conversely, plasma ADAMTS- 13 activity was significantly reduced (median 68.2 IU/dl). 
In keeping with an increase in VWF:ADAMTS- 13 ratio, abnormalities in VWF mul-
timer distribution were common in patients with COVID- 19, with reductions in high 
molecular weight VWF multimers. Terminal sialylation regulates VWF susceptibility 
to proteolysis by ADAMTS- 13 and other proteases. We observed that both N- and 
O- linked sialylation were altered in severe COVID- 19. Furthermore, plasma levels of 
the ADAMTS- 13 inhibitors interleukin- 6, thrombospondin- 1, and platelet factor 4 
were significantly elevated.
Conclusions: These findings support the hypothesis that SARS- CoV- 2 is associated 
with profound quantitative and qualitative increases in plasma VWF levels, and a mul-
tifactorial down- regulation in ADAMTS- 13 function. Further studies will be required 
to determine whether therapeutic interventions to correct ADAMTS- 13-VWF mul-
timer dysfunction may be useful in COVID- microvascular thrombosis and angiopathy.
K E Y W O R D S
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Essentials
• COVID- 19 is associated with a characteristic coagulopa-
thy and acute endothelial cell activation.
• Patients with severe COVID- 19 present with elevated 
plasma von Willebrand factor (VWF) levels and changes 
in multimer distribution.
• COVID- 19 results in a modest reduction in A Disintegrin 
And Metalloprotease with ThrombSpondin Motif type 1 
motif, member 13 (ADAMTS- 13) activity, accompanied 
by increased levels of ADAMTS- 13 inhibitors.
• Therapeutic interventions targeting ADAMTS- 13- VWF 
multimer dysfunction may be beneficial in COVID- - 
microvascular thrombosis.
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VWF multimer distribution is a key determinant of its func-
tional activity. High molecular weight multimers (HMWM) bind 
both collagen and platelet glycoprotein Ib alpha (GPIbα) with sig-
nificantly higher affinity compared to low molecular weight mul-
timers (LMWM). In normal plasma, VWF multimer distribution is 
regulated by the metalloprotease ADAMTS- 13 (A Disintegrin And 
Metalloprotease with ThrombSpondin Motif type 1 motif, member 
13). Dysregulation of VWF proteolysis by ADAMTS- 13 is important 
in the etiology of a number of microangiopathies that share similar 
features to severe COVID- 19 (notably TTP and cerebral malaria).7 
Although several studies have reported elevated plasma VWF levels 
in severe COVID- 19,6,8– 12 the data on VWF multimer patterns is less 
clear. To gain further insights into the potential dysregulation of the 
VWF- - ADAMTS- 13 axis in COVID- 19, we investigated VWF multi-
mer distribution, as well as a series of factors shown to influence the 
susceptibility of VWF to ADAMTS- 13 proteolysis.
2  |  METHODS
Following study approval by the Hospital Research Ethics Committee, 
adult patients with COVID- 19 were recruited from the Beaumont 
Hospital Intensive Care Unit (ICU) in Dublin (demographic and clini-
cal details can be found in Table S1 in supporting information). A 
local control group of 10 healthy individuals (median age of 46 years, 
72% male) was utilized for comparison in this study. All participants 
had a positive SARS- CoV- 2 polymerase chain reaction result and all 
received low molecular weight heparin thromboprophylaxis. Blood 
samples were collected into 3.2% sodium citrate on admission to 
ICU. Plasma VWF:Ag and VWF collagen binding activity (VWF:CB) 
were determined by ELISA and VWF sialylation assessed using 
modified lectin- binding arrays as before.13 VWF multimer analy-
sis was performed as previously described.7 ADAMTS- 13 activity 
was quantified using a commercial FRETS- VWF73 assay (Peptides 
International, Inc.). Plasma interleukin (IL- ) 6, thrombospondin (TSP- ) 
1, and platelet factor 4 (PF4) levels were measured using commer-
cial ELISA kits (R&D Systems). Normally and non- normally distrib-
uted quantitative data were compared using the Student’s t- test 
and Mann- Whitney U test, respectively. Data were analyzed using 
GraphPad Prism 8 and a P- value of <.05 was considered statistically 
significant.
3  |  RESULTS AND DISCUSSION
Twenty- three patients (19 males and 5 females) were included in 
the study with a median age of 55 (range 37– 72) years. Underlying 
comorbidities were evident in 22 patients (96%) with a median co-
morbidity count of 3 (range 0– 4). Four patients developed radiologi-
cally confirmed venous thrombosis during their inpatient stay and 
two patients developed pulmonary embolism following discharge. 
At time of writing 19 patients (82.6%) have been discharged from 
hospital with median length of ICU and hospital stay of 15.5 (range 
2– 79) and 21 (range 6– 125) days, respectively. Three patients died 
during the study.
In keeping with previous reports, plasma VWF:Ag levels were 
markedly elevated in patients with severe COVID- 19 compared to 
healthy controls (median 580 IU/dl [interquartile range (IQR) 360– 
798; P < .0001]; Figure 1A). The VWF:CB assay is a functional 
qualitative assay sensitive to alterations in HMWM. We observed 
that VWF:CB was also significantly increased in COVID- 19 patients 
compared to controls (median 509 IU/dL [IQR 385– 879; P < .0001]; 
Figure 1B). However, significant inter- patient variability was seen 
in the VWF:CB/VWF:Ag ratio (Figure 1C) and despite the marked 
increase in VWF:Ag levels, the VWF:CB/VWF:Ag ratio was not 
significantly increased compared to healthy controls. Interestingly, 
previous studies have reported that increases in qualitative VWF 
ristocetin cofactor activity (VWF:RCo) in COVID- 19 patients are 
consistently lower compared to increases in quantitative plasma 
VWF:Ag levels in the same patients.6,8,11,12,14,15 Together, these 
data suggest that COVID- 19 infection is not only associated with a 
marked quantitative increase in plasma VWF levels, but also impacts 
VWF functional activity.
To further investigate the mechanism(s) underlying this obser-
vation, VWF multimer distribution was analyzed in patients with se-
vere COVID- 19. A number of important differences were observed 
in patients compared to normal control plasma. In particular, a rela-
tive decrease in HMWM was a common feature seen in 18/23 (78%) 
of patients studied (Figure 1D,E). Recent studies have reported 
differences in HMW multimers in patients with severe COVID- 19. 
In keeping with our findings, Doevelaar et al. reported loss of the 
largest VWF multimers in 75% of patients with severe COVID- 19.16 
Similarly, Mancini et al. found that HMWM decreased progressively 
with increasing intensity of supportive care required.8 In contrast, 
however, Philippe et al. reported significantly higher VWF HMWM 
in critical COVID- 19 patients compared to non- critical controls.9 
Further studies will be necessary to elucidate the explanations un-
derlying these findings. However, it seems likely that they may relate 
in part to differences in the patient cohorts studied, the timing of 
sample collection, and the methods utilized for VWF multimer anal-
ysis. A similar loss of HMWM has been described in patients with 
acute TTP where it has been attributed to consumption of hyper- 
active HMWM multimers binding to platelet GPIbα causing platelet 
adhesion and subsequent aggregation leading to microthrombi and 
blood vessel occlusion.17 It seems possible that similar consump-
tion of HMWM VWF may be occurring in COVID coagulopathy. 
Importantly, ultra- large (UL- ) VWF multimers were not observed in 
any of our patients with severe COVID- 19, which is consistent with 
previous studies.8,16 However, an increase in LMWM VWF and a 
smearing of the normal VWF triplet pattern were observed on mul-
timer analysis for all COVID- 19 patients (Figure 1D). Taken together, 
these data suggest that severe COVID- 19 is associated with con-
sumption of HMWM, but also that it impacts in other ways upon 
normal VWF proteolysis in vivo.
Following secretion from EC, ultra- large VWF multimers nor-
mally undergo partial proteolysis by ADAMTS- 13. Consequently, we 
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F I G U R E  1  A, Plasma von Willebrand factor antigen (VWF:Ag), B, collagen binding activity, and D,E, multimer distribution in patients 
with severe COVID- 19. Plasma samples were collected from patients with severe COVID- 19 following admission to the intensive care unit 
and compared to healthy controls. Data are presented as median and the interquartile range unless otherwise stated (***P < .001). Asterisk 
symbols on multimer lanes indicate pronounced abnormal smearing of triplet structure bands, also shown in inset image. MWM, molecular 
weight multimers; NPP, normal pooled plasma; VWF:CB, VWF collagen binding activity
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F I G U R E  2  A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS- 13) regulation of von 
Willebrand factor (VWF) multimers in patients with severe COVID- 19. A– C, ADAMTS- 13 activity was reduced in patients with severe 
COVID- 19 resulting in an increased VWF/ADAMTS- 13 ratio with a direct inverse correlation. D & E, Altered N- and O- linked VWF sialylation 
was observed in COVID- 19 patients. F– J, Elevated levels of ADAMTS- 13 inhibitors, IL- 6, TSP- 1, and PF4 were observed and TSP- 1 and PF4 
levels correlated significantly with ADAMTS- 13 activity. IL- 6, interleukin- 6; MAA, Maackia amurensis; PF4, platelet factor 4; SNA, Sambucus 
nigra agglutinin; TSP- 1, thrombospondin- 1. *P < .05, **P < .01, ***P < .001, ****P < .0001
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next investigated ADAMTS- 13 activity in patients with SARS- CoV- 2 
infection. In keeping with previous studies, significantly reduced 
ADAMTS- 13 activity was seen in patients with severe COVID- 19 com-
pared to controls (median 68.2% [IQR 56– 78; P < .001]; Figure 2A). 
Reduced plasma ADAMTS- 13 levels have previously been reported 
in association with other types of sepsis including Plasmodium falci-
parum malaria and Dengue virus. Lower ADAMTS- 13 activity in se-
vere COVID- 19 is likely to be attributable in part to reduced hepatic 
ADAMTS- 13 synthesis. However, increased ADAMTS- 13 consump-
tion or clearance leading to deficiency has also been previously asso-
ciated with markedly elevated plasma VWF levels, which is a hallmark 
of severe COVID- 19. Moderately reduced ADAMTS- 13 levels were 
a consistent finding in severe COVID- 19 infection in which all our 
patients had residual ADAMTS- 13 activity levels above 50 IU/dl 
compared to TTP patients, whose levels are reduced to less than 
10 IU/dl. However, under high shear induced blood flow conditions, 
much higher ADAMTS- 13 levels are required to effectively cleave 
ultra large VWF multimers released from EC that could potentially 
mediate COVID- 19 thrombosis.18
This mechanism may be important when considered in the con-
text of the massively increased plasma VWF levels. In contrast to 
other types of sepsis, severe COVID- 19 thus results in a major in-
crease in the VWF/ADAMTS- 13 ratio (Figure 2B) and a significant 
inverse correlation was observed between VWF:Ag levels and 
ADAMTS- 13 activity (Figure 2C). Moreover, this imbalance between 
substrate and enzyme under high shear stress is likely to be even 
more pronounced in the lung microvasculature where EC damage is 
most evident.
ADAMTS- 13 regulates multimer distribution by specifically 
cleaving VWF at the Tyr1605- Met1606 bond within the A2 domain. 
This cleavage site is flanked by two N- linked glycan sites (N1515 
and N1574 in A2). Terminal sialic acid residues on these N- glycan 
chains have been shown to regulate the susceptibility of VWF to 
ADAMTS- 13 proteolysis.19 The Sambucus nigra agglutinin (SNA) lec-
tin has specific affinity for terminal α2- 6 linked sialic acid. This type 
of sialic acid accounts for approximately 80% of the total sialylation 
on human VWF and is predominantly expressed on N- glycans.20 We 
observed significantly enhanced SNA binding to VWF in patients 
with severe COVID- 19 compared to controls (median 114.7% [IQR 
87– 144; P < .05]; Figure 2D). In contrast, Maackia amurensis lectin 
II (MAA- II; affinity for terminal α2- 3 linked sialic acid on VWF O- 
glycans) binding to VWF was significantly reduced in COVID- 19 pa-
tients (median 71.8% [IQR 55– 85; P < .05]; Figure 2E). Collectively, 
these data suggest that the post- translational processing of VWF 
within EC is altered in severe COVID- 19, which is perhaps unsur-
prising given the marked increase in VWF biosynthesis and EC dam-
age that are features of the condition. Altered VWF sialylation in 
severe COVID- 19 has important biological relevance. First, α2- 6 
sialylation expression on VWF has been shown to influence suscep-
tibility to proteolysis by ADAMTS- 13 and other proteases.19 In par-
ticular, sialyation has been shown to protect VWF from proteolysis 
by plasmin21 and recent studies have reported markedly elevated 
plasmin generation in patients with severe COVID- 19.22 Second, 
hypersialylation also results in an extended VWF half- life, which has 
recently been reported in patients with severe COVID- 19.5 Finally, 
platelet- derived VWF has significantly reduced α2- 6 sialic acid ex-
pression compared to EC- derived VWF.23 Consequently, our data 
suggest that the markedly elevated plasma VWF levels observed in 
SAR- CoV- 2 patients predominantly result from EC rather than plate-
let activation.
In addition to VWF glycosylation, a number of other putative 
regulators of ADAMTS- 13 activity have been reported. For exam-
ple, high levels of IL- 6, TSP- 1, and PF4 have been shown to inhibit 
ADAMTS- 13.24- 26 We observed that plasma levels of IL- 6 were sig-
nificantly elevated in patients with severe COVID- 19 compared to 
controls (median 198.1 pg/ml [IQR 80– 385; P < .05]; Figure 2F). 
Although plasma IL- 6 levels were increased, absolute concentrations 
did not reach those necessary to inhibit ADAMTS- 13 activity (>50 ng/
ml).24 Similarly, plasma TSP- 1 levels were also elevated in COVID- 19 
patients (median 1824.9 ng/ml [IQR 1537– 2153; P < .001]) and TSP- 1 
levels inversely correlated with ADAMTS- 13 activity25 (Figure 2H). 
Finally, plasma PF4 levels were significantly elevated in patients with 
severe COVID- 19 compared to healthy controls (median 652.6 ng/
ml, [IQR 270.6– 1263]; P < .0001; Figure 2I). Moreover, PF4 levels 
also were inversely correlated with ADAMTS- 13 activity (P = .03; 
Figure 2J). These data suggest that high concentrations TSP- 1 re-
leased from perturbed vascular EC or elevated PF4 levels secreted 
from activated platelets may inhibit in vivo ADAMTS- 13 activity in 
patients with severe COVID- 19. Furthermore, coagulation and fibri-
nolytic cascade activation are prominent features of COVID- 19 co-
agulopathy. This is relevant as previous studies have demonstrated 
that ADAMT- 13 is susceptible to proteolytic inactivation by both 
thrombin and plasmin.21,27 Consequently, our data support the hy-
pothesis that ADAMTS- 13 regulation of VWF multimer distribution 
is impacted through multiple mechanisms in patients with severe 
COVID- 19.
In conclusion, our findings demonstrate that SARS- CoV- 2 is 
associated with profound quantitative and qualitative increases 
in plasma VWF levels. In addition, severe COVID- 19 also down- 
regulates ADAMTS- 13 function through a variety of different mech-
anisms. Importantly, consumption of HMWM- - VWF is a common 
feature in patients with severe COVID- 19 infection requiring ICU 
support. Thus, plasma VWF multimer distribution in these patients 
is similar to that typically associated with acute TTP. Further stud-
ies will be required to determine whether therapeutic interventions 
targeted at reversing ADAMTS- 13 dysfunction may constitute a 
useful adjunctive measure in the management of COVID- induced 
microangiopathy.
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